Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.

Goldstein S, Bates ER, Bhatt DL, Cao C, Holmes D, Kupfer S, Martinez F, Spaeder J, Weitz JI, Ye Z, Zannad F; AXIOM investigators.

Thromb Haemost. 2014 Jun;111(6):1141-52. doi: 10.1160/TH13-07-0543. Epub 2014 Mar 27.

PMID:
24671450
2.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators.

N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25.

3.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

Supplemental Content

Loading ...
Support Center